Aandelen in “Productie van biologische producten”

Aandeel Datum Koers Evolutie
vlag Beam Therapeutics Inc 31/10 25,010 USD
+5,08% 		+5,08%
vlag Bio-Techne Corp 31/10 62,570 USD
+2,64% 		+2,64%
vlag Biocryst Pharmaceuticals Inc. 31/10 7,320 USD
+0,97% 		+0,97%
vlag Biogen 31/10 154,270 USD
+3,11% 		+3,11%
vlag BioNTech SE 31/10 103,910 USD
-0,73% 		-0,73%
vlag Brainstorm Cell Therapeutics, Inc. 31/10 0,650 USD
-0,51% 		-0,51%

Nieuws over “Productie van biologische producten”

15:15 · Cellectis to Present a Development Update for eti-cel at ASH 2025 · Persbericht

15:15 · Cellectis to Present a Development Update for eti-cel at ASH 2025 · Persbericht

15:00 · Pierre Fabre Pharmaceuticals Announces Transfer from Atara Biotherapeutics of the Biologics License Application (BLA) for Tabelecleucel as Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) · Persbericht

13:30 · Biogen to Highlight Scientific Progress in Rare Kidney Disease at American Society of Nephrology (ASN) Kidney Week 2025 · Persbericht

13:00 · ScaleReady Announces a G-Rex® Grant has been awarded to Sonoma Biotherapeutics · Persbericht

31/10 · Cellectis to Report Third Quarter Financial Results on November 7, 2025 · Persbericht

31/10 · AMGEN ANNOUNCES 2025 FOURTH QUARTER DIVIDEND · Persbericht

31/10 · AMGEN'S LANDMARK PHASE 3 REPATHA DATA TO BE PRESENTED AS LATE BREAKER AT THE AMERICAN HEART ASSOCIATION SCIENTIFIC SESSIONS 2025 · Persbericht

30/10 · DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors · Persbericht

30/10 · GENFIT announces intention to voluntarily delist American Depositary Shares from The Nasdaq Global Select Market · Persbericht

30/10 · Curis to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on November 6, 2025 · Persbericht

30/10 · Novavax to Report Third Quarter 2025 Financial Results on November 6, 2025 · Persbericht

30/10 · REGENXBIO Announces Completion of Pivotal Enrollment and Initiates Commercial Production in Duchenne Gene Therapy Program · Persbericht

30/10 · Argenx stuwt Bel20 weer naar 5.000 punten · Tijd.be (€)

Een sterk rapport en bijbehorende recordkoers voor Argenx kleuren de Bel20 groen. Bij een ander zwaargewicht, AB InBev, countert een verwenbeurt voor de belegger een flets rapport.

30/10 · DBV Technologies to Participate in Upcoming ACAAI 2025 Annual Scientific Meeting · Persbericht

30/10 · Argenx imponeert met miljard dollar kwartaalomzet · Tijd.be (€)

Het Gentse biotechbedrijf Argenx heeft voor het eerst meer dan een miljard dollar omzet gehaald in één kwartaal. Ook de winstmotor begint volop te draaien.

29/10 · DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq · Persbericht

29/10 · AMGEN ANNOUNCES WEBCAST OF 2025 THIRD QUARTER FINANCIAL RESULTS · Persbericht

29/10 · REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2025 Financial Results and Operational Highlights · Persbericht

28/10 · GENFIT Announces Advances Across its ACLF Pipeline at AASLD The Liver Meeting® 2025 · Persbericht

28/10 · DBV Technologies Reports Third Quarter 2025 Financial Results · Persbericht

Mijn selecties